Endocannabinoids and lipid mediators in brain functions
The science of cannabinoids is 50 years old. These past years provided a remarkable and constant number of breakthroughs, showing that the signaling mediated by endocannabinoids and lipid mediators impacts almost every function of the body. Indeed, this represents a special field of research, which...
Saved in:
| Other Authors | |
|---|---|
| Format | Electronic eBook |
| Language | English |
| Published |
Cham :
Springer,
2017.
|
| Subjects | |
| Online Access | Full text |
| ISBN | 9783319573717 9783319573694 |
| Physical Description | 1 online resource |
Cover
| LEADER | 00000cam a2200000Mi 4500 | ||
|---|---|---|---|
| 001 | 97343 | ||
| 003 | CZ-ZlUTB | ||
| 005 | 20251008101053.0 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 170602s2017 sz ob 000 0 eng d | ||
| 040 | |a YDX |b eng |e pn |c YDX |d N$T |d EBLCP |d N$T |d GW5XE |d UAB |d ESU |d AZU |d UPM |d IOG |d COO |d MERER |d OCLCQ |d U3W |d CAUOI |d OCLCQ |d OCLCF |d KSU |d VT2 |d AU@ |d WYU |d OCLCQ |d AUD |d UKMGB |d UKAHL |d OCLCQ |d ERF |d OCLCQ |d SRU | ||
| 020 | |a 9783319573717 |q (electronic bk.) | ||
| 020 | |z 9783319573694 | ||
| 024 | 7 | |a 10.1007/978-3-319-57371-7 |2 doi | |
| 035 | |a (OCoLC)988850920 |z (OCoLC)988600476 |z (OCoLC)989031945 |z (OCoLC)992453475 |z (OCoLC)992889505 |z (OCoLC)999547115 |z (OCoLC)1005792445 |z (OCoLC)1011954145 |z (OCoLC)1048136198 |z (OCoLC)1058607665 |z (OCoLC)1066690166 |z (OCoLC)1097143489 |z (OCoLC)1112508873 | ||
| 245 | 0 | 0 | |a Endocannabinoids and lipid mediators in brain functions / |c Miriam Melis, editor. |
| 260 | |a Cham : |b Springer, |c 2017. | ||
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a počítač |b c |2 rdamedia | ||
| 338 | |a online zdroj |b cr |2 rdacarrier | ||
| 505 | 0 | |a Endocannabinoids and Lipid Mediators in Brain Functions; Contents; List of Committed Contributors; The Endocannabinoid System in Leptin-Driven Changes of Orexinergic Signaling Under Physiological and Pathological Conditions; 1 Endocannabinoids and Cannabinoid Receptor Type 1: An Overview; 2 Orexin/Hypocretin: Discovery and Characterization; 3 Orexin Receptors: Common Signaling with CB1; 4 Anatomical Overlap Between Cannabinoid and Orexin Receptor Distribution in the Brain; 5 Molecular Interactions Between Cannabinoid and Orexin Receptors. | |
| 505 | 8 | |a 6 Functional Interaction Between Cannabinoid and Orexin Receptors Under Leptin Signal Deficiency: Emerging Studies6.1 Appetite and Energy Homeostasis; 6.2 Reward, Arousal, and Seeking Behavior; 6.3 Sleep/Wakefulness; 6.4 Nociception; References; How CB1 Receptor Activity and Distribution Contribute to Make the Male and Female Brain Different Toward Cannabinoid-Induced E ... ; 1 Brain Sexual Dimorphisms and the Endocannabinoid System; 2 Sex-Dependent Effects of Cannabinoids; 3 CB1R Density and Function in the Male and Female Brain; 3.1 Prefrontal Cortex; 3.2 Thalamus; 3.3 Hypothalamus. | |
| 505 | 8 | |a 3.4 Hippocampus3.5 Amygdala; 3.6 Periaqueductal Gray; 3.7 Nucleus Accumbens; 3.8 Ventral Tegmental Area; 3.9 Cerebellum; 3.10 Basal Ganglia; 4 Hormonal Influence on CB1Rs; 5 Conclusions; References; Endocannabinoids, Stress, and Negative Affect; 1 Neuroendocrine Response to Stress; 2 Introduction to the Endocannabinoid System; 3 Role of the Endocannabinoid System in the Acute Effects of Stress; 4 Role of the ECB System in the Effects of Chronic Stress; 5 Stress-Related Negative Affect and Drug Withdrawal; 5.1 Stress-Related Negative Affective Behavior; 5.2 Drug Withdrawal. | |
| 505 | 8 | |a 5.3 Sex Differences in Negative Affect and Drug Withdrawal6 Implications for the Development of ECB-Based Therapeutics; 7 Summary; References; Cell-Autonomous Endocannabinoid Production Shapes Polarized and Dynamic Distribution and Signaling Patterns of Cannabinoid CB1 ... ; 1 Polarized Distribution of Neuronal Plasma Membrane Components; 2 GPCR Activation State Depends on the Plasma Membrane Environment; 3 The CB1 Cannabinoid Receptor: A Structurally Instable GPCR; 4 Ubiquitous Neuronal Membrane Component Endocannabinoids Produce Tonic CB1 Activation. | |
| 505 | 8 | |a 5 Subcellular Distribution of Neuronal CB1 Receptors6 Polarized CB1 Targeting in Neurons; 7 Polarized CB1R Signaling in Neurons; 8 A Special Case: CB1 at the Presynaptic Terminal; 9 Conclusion; References; Endocannabinoid-Dependent Synaptic Plasticity in the Striatum; 1 Introduction; 1.1 The Endocannabinoid System in the Striatum; 1.1.1 Striatal Neurons; 1.2 Endocannabinoid System Expression in the Striatum; 2 Cannabinoid Receptor-Mediated Regulation of Synaptic Transmission; 2.1 Effects of Cannabinoids on GABAergic and Glutamatergic Synaptic Transmission. | |
| 506 | |a Plný text je dostupný pouze z IP adres počítačů Univerzity Tomáše Bati ve Zlíně nebo vzdáleným přístupem pro zaměstnance a studenty | ||
| 520 | |a The science of cannabinoids is 50 years old. These past years provided a remarkable and constant number of breakthroughs, showing that the signaling mediated by endocannabinoids and lipid mediators impacts almost every function of the body. Indeed, this represents a special field of research, which allows tackling the complexity of biological functions, and provides potential therapeutic frameworks for a plethora of diseases. The number of exciting discoveries brought up to the scientific community almost on a daily basis highlights the importance of an updated volume on this topic. Particularly, given that potential therapeutic benefits of cannabis and cannabinoids are currently under heavy analysis in many Countries worldwide. Hence, the main objective of this book is to explore not only some of the many functions of endocannabinoids (and lipid mediators) in physiological control of networks at a cellular and molecular level, but also to extend this knowledge for potential use of cannabinoids and/or drugs regulating endocannabinoid levels in vivo as therapeutic target(s) in neurological and neuropsychiatric disorders. In this book new findings and ideas about the endocannabinoid system and its roles as neuronal circuit modulator related to human brain pathologies characterized by alterations in neuroplasticity will be highlighted. Endocannabinoid roles in key systems controlling appetite, pain, learning and memory, as well as sleep and stress responses will be presented. In addition, pathological processes associated with changes in endocannabinoid signaling will be discussed in the context of anxiety, autism, depression and addiction. This book will provide an excellent background to researchers looking for extending their areas of interest, and to newcomers in the field. | ||
| 504 | |a Includes bibliographical references at the end of each chapters. | ||
| 590 | |a SpringerLink |b Springer Complete eBooks | ||
| 650 | 0 | |a Cannabinoids |x Physiological effect. | |
| 650 | 0 | |a Cannabinoids |x Receptors. | |
| 650 | 0 | |a Brain. | |
| 655 | 7 | |a elektronické knihy |7 fd186907 |2 czenas | |
| 655 | 9 | |a electronic books |2 eczenas | |
| 700 | 1 | |a Melis, Miriam. | |
| 776 | 0 | 8 | |i Print version: |t Endocannabinoids and lipid mediators in brain functions. |d Cham : Springer, 2017 |z 9783319573694 |z 3319573691 |w (OCoLC)981117505 |
| 856 | 4 | 0 | |u https://proxy.k.utb.cz/login?url=https://link.springer.com/10.1007/978-3-319-57371-7 |
| 992 | |c NTK-SpringerBLS | ||
| 999 | |c 97343 |d 97343 | ||
| 993 | |x NEPOSILAT |y EIZ | ||